If you’re eyeing Pfizer stock and wondering what’s next, you’re definitely not alone. The last few years have been a roller ...

Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...

Pfizer enters the obesity drug market with a reasonably valued deal, while valuation remains attractive and technicals show ...

After its best day in nearly four years Tuesday, Pfizer stock gave an encore performance. Shares of the drugmaker closed u ...

QSM Asset Management added 276,899 shares of Pfizer for an estimated $6.8 million in the third quarter. After the transaction ...

Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.

Pfizer Inc. is a global biopharmaceutical leader with a diversified product portfolio and significant scale, supported by ...

President Donald Trump announced a deal with Pfizer to lower drug prices for some Americans. The White House is also unveiling a TrumpRx website.

Pfizer will reduce prices on drugs sold to Medicare patients. The Trump administration has made cutting prescription drug prices a priority. Ultimately, the administration aims to have Americans ...

Investors continued to be positive on the pharmaceutical giant following a deal reached with the government. Among other benefits, it will have a reprieve from potential tariffs on its industry. On ...